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Background. Evidence-based guidelines should in most cases be followed also in the treatment of elderly. Older people are often
suboptimally treated with the recommended drugs. Objectives. To describe how well general practitioners adhere to current
guidelines in the treatment of elderly with cardiovascular disease and evaluate local education as a tool for improvement. Method.
Data was collected from the medical records of patients aged ≥65, who visited a primary health care center in Sweden 2006 and
had one or more of the following diagnoses: hypertension, ischemic heart disease, heart failure, chronic atrial ﬁbrillation, or prior
stroke. Local education was organized and included feed-back to the patient’s doctor and discussion about regional guidelines.
Repeated measurements were performed in 2008. Results and Conclusion. The adherence to guidelines was low. Approximately
one-third of the patients with hypertension reached target blood pressure, stroke patients more often. More patients with heart
failure were treated with angiotensin converting enzyme inhibitor than in other European countries, but still only 60%. Half of the
patients with chronic atrial ﬁbrillation were treated with Warfarin, although more than two-thirds had a CHADS2 score indicating
the need. Educational eﬀorts appeared to increase the adherence and hence should be encouraged.
1.Introduction
Manyelderlyaretreatedwithseveraldiﬀerentdrugs.Withan
increase in the number of medicines, there is a greater risk of
interactions and adverse eﬀects. There are however also risks
associated with the underuse of recommended treatment.
For several diseases, it has been shown that it is more
common for elderly than for younger patients to receive
suboptimal treatment with the recommended drugs [1–
3]. Regional guidelines for the treatment of cardiovascular
diseases, built on evidence based data, should in most cases
befollowedalsointhediagnosisandtreatmentofelderly[4].
Hypertension is a well-documented risk factor for cardio-
vascular disease. There is strong evidence that elderly beneﬁt
from antihypertensive treatment at least as much as younger
do, probably due to higher risk for cardiovascular events
[5]. The recommendation is a target blood pressure (BP) of
130/80forpatientswithdiabetesandof140/90forothers[4].
However, recent research has shown that lower systolic blood
pressure (SBP) seems to be associated with greater mortality
in patients aged 85 or more, irrespective of health status. An
optimal SBP for this age group could be above 140mmHg
[6].
The recommendation for ischemic heart disease is treat-
ment with aspirin, beta-blocker, and, if the cholesterol level
is above recommended, also statin [4]. There is evidence for
lowered mortality and morbidity using such treatment, even
if only a small number of patients in studies about coronary
disease are more than 75 years old.
For the diagnosis heart failure, cardiac dysfunction has
to be objectively conﬁrmed. The recommended method is
echocardiography (ECO). Recommended pharmacological
therapy for heart failure is angiotensin converting enzyme
inhibitors (ACEIs) which have a well-established eﬀect on
mortality and morbidity [4, 7]a n df o rN Y H A( N e wY o r k
Heart Association) functional class II-IV also beta-blockers.
NYHA functional classiﬁcation grades the severity of heart
failure symptoms. Unfortunately ACEIs are often underused2 The Scientiﬁc World Journal
for older patients and especially in nursing homes [2].
Diuretics are overused instead.
For patients with chronic atrial ﬁbrillation, anticoag-
ulation should be given to lower the risk of stroke [4].
This risk is depending on age and comorbidity and can be
calculated with the CHADS2 score, giving one point each
for the presence of congestive heart failure, hypertension,
age 75 years or older, and diabetes mellitus, and two points
for history of stroke or transient ischemic attack (TIA) [8].
Warfarin is indicated at a score of two points or more.
Although warfarin has the most positive eﬀect in the elderly,
only half of the patients in this age group are treated with
warfarin, compared to 85% in the group 45–65 years [9]. If
warfarin is contraindicated, aspirin in the dose 320mg per
daycouldbeconsideredaccordingtotheguidelines2006[4].
Aspirin is also the best documented secondary preven-
tion of stroke [10] in combination with lowering the blood
pressure to target 140/90 [4].
This study was performed as a quality improvement
project on a middle-sized family health care centre. We
wanted to describe how well general practitioners (GPs)
adhere to current guidelines when they investigate and treat
elderly patients with cardiovascular disease. We also wanted
to evaluate feedback and local continuing education as an act
for improvement of this treatment.
2. Methods
The study was performed in 2006–2008 in a family health
care center in Esl¨ ov, a municipality in southern Sweden with
a population of approximately 30 000. The center has a
registered population of 10500. All nine GPs at the center
participated in the intervention. Data was collected from the
patient’s medical records on patients who met the following
inclusion criteria:
(i) ≥65 years,
(ii) visited the health care center between April (July for
hypertension) and December 2006,
(iii) on this visit, received one or more of the following
diagnoses: hypertension, heart failure (HF), ischemic
heart disease (IHD), chronic atrial ﬁbrillation (CAF),
or prior stroke (inclusive TIA).
Forthediagnosishypertension,patientswhoreceivedthe
diagnosis less than 6 months ago were excluded.
2.1. Measurements and Procedure. The medical records were
systematically reviewed by a doctor and the following vari-
ables were investigated, as recommended in the guidelines of
2006.
For hypertension:
(i) Target blood pressure reached (130/80 for diabetes
and 140/90 for others)?
(ii) If not, number of antihypertensive drugs?
(iii) ECG during the last 2 years?
(iv) Blood lipids tested during the last 5 years?
For ischemic heart disease:
(i) Diagnosis based on cardiac stress test/myocardial
scintigraphy/prior veriﬁed acute myocardial infarc-
tion?
(ii) Treated with betablocker?
(iii) Treated with aspirin (or clopidogrel/warfarin)?
(iv) Blood lipids tested during the last 5 years?
(v) Target level for cholesterol reached (LDL
≤2.5mmol/L and total cholesterol ≤4.5mmol/L)?
For heart failure:
(i) Diagnostics performed: Echocardiography
performed ever? NT-proBNP tested ever? Pulmonary
X-ray performed initially?
(ii) Treated with ACEI or, if intolerant, angiotensin
receptor blocker (ARB)?
(iii) Target dose used for ACEI/ARB?
(iv) Treated with betablocker with indication for HF?
(v) Treated with NSAID regularly?
For chronic atrial ﬁbrillation:
(i) Treated with warfarin? If no, treated with aspirin
320mg?
(ii) Which CHADS2-score does the patient reach?
For stroke:
(i) Target blood pressure 140/90 reached?
(ii) If ischemic stroke: Treated with recommended anti-
coagulation (aspirin 160mg, warfarin or clopido-
grel)?
Any information not easily accessible in the medical
records was regarded as missing. Only a very small number
of patients (<10) were excluded due to insuﬃcient quality of
data.Patientswithhypertensionweredividedintoonegroup
with patients aged 65–84 and one group aged 85 or more.
This was due to the recent research ﬁnding that the oldest
elderly perhaps do not gain from a blood pressure treated to
the same low target as younger adults [6].
2.2. Intervention. I fc u r r e n tr e c o m m e n d a t i o n sw e r en o t
followed, feed-back was given to the patient’s doctor with
suggestions for possible improvements. Local education was
organized in 2007 for all clinicians at the health center,
focusing on cases and the regional guidelines. The education
was repeated and followed up after three months. Repeated
measurements were performed for the patients who visited
the health care center between April and December 2008.
2.3. Statistics. Power calculations for changes in proportions
of adherence to guidelines were performed before the study
started.Foreachdiagnosisonevariablewasconsideredasthe
main variable. These were for hypertension the proportion
who reached target blood pressure, for IHD treatment withThe Scientiﬁc World Journal 3
beta blocker, for heart failure treatment with ACEI/ARB,
for CAF treatment with warfarin, and for stroke reaching
target blood pressure. The proportion of the main variable
was analyzed in a smaller sample. The power calculation
was performed on clinically reasonable improvements in
the variables. For example, the proportion who reached
target blood pressure in the sample was 35% and a clinically
relevant proportion in the hypertension population should
be 60%. The observation period was set up in order to get
suﬃcient number of patients. It was enough to investigate a
random sample of every ﬁfth patient with hypertension aged
65–84. For IHD, HF, and CAF adequate numbers of patients
were available during the observation period. Enough stroke
patients were not found at the center to expect signiﬁcant
changes. Observed proportions of adherence and their exact
conﬁdence limits were calculated. The proportions from
the studied periods were compared using two-sample test
for equality of proportions. Computer software R version
2.6.0 was used for all statistical analyses (R Foundation for
Statistical Computing, Vienna, Austria).
2.4. Ethics. The study did not require an ethical approval
according to a protocol by the ethical committee of Lund
University no. 228/2007. The study was performed in
accordance with Swedish law and the declaration of Helsinki.
3. Results
Characteristics of the patients with hypertension are pre-
sentedinTable 1.Approximatelyone-thirdreachedtargetBP.
Of those who did not reach target BP and were aged 65–84,
29% (8/28) had monotherapy in 2006 and 34% (12/35) in
2008. Of those aged 85 or more and who did not reach target
BP, 53% (8/15) had monotherapy in 2006 and 36% (10/28)
in 2008.
The measurements of 2006 and 2008 of the patients
with ischemic heart disease are presented in Table 2.T h e
treatment with beta blocker and especially aspirin was stable
and high.
For patients with HF, treatment with beta blocker
increased. Characteristics of HF patients are shown in
Table 3. Of these patients 76% (2006) and 88% (2008),
respectively, had been examined with pulmonary X-ray as a
part of the investigations for diagnosis. No patient with heart
failure was treated with NSAIDs regularly in 2006 and one
patient was in 2008. Of the patients treated with ACEI/ARB
sixteen out of forty-ﬁve (36%) were treated up to target dose
in 2006 and twenty-three out of sixty-seven (34%) in 2008.
The measurements in 2006 and in 2008 of the patients
with chronic atrial ﬁbrillation or prior stroke are presented
in Table 4. For stroke, the diﬀerence between 2008 and 2006
is not presented, since there were too few stroke patients
at the center to expect signiﬁcant changes. Approximately
one-third of the stroke patients reached target BP. About
half of the CAF patients were treated with warfarin. Patients
with lower CHADS2-score were often treated with warfarin.
Table 5 presents the number of CAF patients with diﬀerent
CHADS2-score, who are treated with Warfarin, aspirin
320mg, or no recommended anticoagulation, respectively.
4. Discussion
As previously described in other studies in primary care, the
adherence to guidelines for the treatment of cardiovascular
disease was low in this study. In addition, the study revealed
that educational eﬀorts may have a positive impact on the
adherence and therefore should be encouraged.
The study was performed as a quality improvement
project on a family health care station. We applied the
regional guidelines of 2006. These are built on evidence-
based data and widely known guidelines of international
societies.
In 2006, the recommendation for the treatment of
hypertension was a target BP of 130/80 for patients with
diabetes and 140/90 for others. For patients aged between
65 and 80, we found a trend of more patients reaching
target level after the education intervention (28% in 2006
versus 35% in 2008) but this was not signiﬁcant (P = 0.63).
For patients aged above 80 however, the trend was rather
in the opposite direction. The modest amount of values
reachingtargetlevelisinagreementwithapriorstudywithin
primary healthcare in southern Sweden in 2006, where only
20% of the treated hypertensives reached target level of BP
[11]. In that study, 40% of the patients had monotherapy,
although combination treatment is recommended. This is in
agreement with our ﬁndings: one-third of the patients not
reaching target level did not have combination treatment in
2008. Another Swedish study also found that old age of the
patient seemed to be an important barrier among GPs when
considering pharmacological treatment for the management
of hypertension [12].
The Hypertension in the Very Elderly Trial (HYVET)
revealed that using antihypertensive drug therapy decreases
theriskofnewcardiovasculareventsaswellastotalmortality
in the elderly (over 80) [13]. The HYVET study, however,
does not provide data on a target BP for these elderly.
Molander et al. found that an SBP level of 162 was associated
with the lowest mortality in the patient group aged above 85
[6]. The question arises whether many GPs already consider
this BP level ideal for this elderly group. HYVET subjects
were generally rather healthy. Therefore, it is important to
note that results cannot be extrapolated to the frail elderly
[14]. GPs might restrict the blood pressure treatment when
patients have extensive comorbidity.
Treating blood pressure to target is important in sec-
ondary prevention of stroke. The HYVET study showed
a 30% reduction in strokes in the treatment group [13].
Therefore the proportion of patients with prior stroke
reaching target BP 140/90 should be higher in our study. The
proportion was 62% (2006) and 68% (2008), respectively.
The physicians seemed more eager to treat to target in the
population with prior stroke, than in the population with
only hypertension. Another Swedish study showed that the
incidence of ﬁrst-ever stroke was strongly related to poor
BP control. It was estimated that 45% to 52% of all strokes
among pharmacological-treatedpatients wereattributableto
uncontrolled blood pressure [15].
Inthepatientgroupover80withhypertension,wefound
a signiﬁcant improvement from 2006 to 2008 in testing of4 The Scientiﬁc World Journal
Table 1: Patients with hypertension who reach target blood pressure and are investigated with ECG and blood lipids.
N Percentage (95%CI) Diﬀerencea (95%CI) P value
Patients 65–84 years
Total number of patients 2006 39
2008 54
Target blood pressure level 2006 11 28.2 (15.0, 44.9) 7.0 (−14.2, 28.2) 0.63
2008 19 35.2 (22.7, 49.4)
ECG taken last two years 2006 17 43.6 (27.8, 60.4) −4.7 (−27.2, 17.8) 0.81
2008 21 38.9 (25.9, 53.1)
Lipids assessed 2006 29 74.4 (57.9, 87.0) 1.6 (−17.8, 21.0) 1
2008 41 75.9 (62.4, 86.5)
Patients ≥85 years
Total number of patients 2006 24
2008 41
Target blood pressure level 2006 9 37.5 (18.8, 59.4) −5.8 (−33.1, 21.6) 0.31
2008 13 31.7 (18.1, 48.1)
ECG taken last two years 2006 14 58.3 (36.6, 77.9) −7.1 (−35.4, 21.2) 0.77
2008 21 51.2 (35.1, 67.1)
Lipids assessed 2006 3 12.5 (2.7, 32.4) 26.5 (3.3, 49.8) 0.047
2008 16 39.0 (24.2, 55.5)
aDiﬀerence between 2008 and 2006.
Table 2: Patients with ischemic heart disease who are pharmacologically treated and investigated according to the guidelines.
N Percentage (95%CI) Diﬀerencea (95%CI) P value
Number of patients 2006 113
2008 105
Investigation performed 2006 105 92.9 (86.5, 96.9) 0.54 (−8.0, 6.9) 1
2008 97 92.4 (85.5, 96.7)
Treated with beta blocker 2006 70 61.9 (52.3, 70.9) 10.5 (−2.9,23.7) 0.14
2008 76 72.4 (62.8, 80.7)
Treated with aspirin 2006 100 88.5 (81.1, 93.7) −1.8 (−11.5, 7.9) 0.84
2008 91 86.7 (78.6, 92.5)
Treated with aspirin/warfarin 2006 107 94.7 (88.8, 98.0) −1.4 (−8.6, 5.9) 0.89
2008 98 93.3 (86.7, 97.3)
Lipids assessed 2006 84 74.3 (65.3, 82.1) 6.6 (−5.3, 18.5) 0.31
2008 85 81.0 (72.1, 88.0)
Target lipid level 2006 32/84 38.1 (27.7, 49.3) 9.0 (−7.1, 25.0) 0.31
2008 40/85 47.1 (36.1, 58.2)
aDiﬀerence between 2008 and 2006.
thepatient’slipidlevel.Thisisnotthemostimportantpartof
the intervention but it reveals that the educational program
has an eﬀect.
The positive trend of increased lipid level testing, as
well as treatment to lipid target level, was also seen among
the patients with IHD. For these patients, we also found
a positive trend for the treatment with beta-blocker, from
62% in 2006 to 72% in 2008 (not signiﬁcant). This is more
than was seen in Finland 2003, where 51% of patients with
IHD aged 75 and above were treated with beta-blocker [16].
Aspirin treatment or other anticoagulation was in our study
stable and high in 2006 as well as in 2008.
Remme et al. found that despite the widespread avail-
ability of evidence-based guidelines, there are diﬀerencesThe Scientiﬁc World Journal 5
Table 3: Patients with chronic heart failure who are pharmacologically treated and investigated according to the guidelines.
N Percentage (95%CI) Diﬀerencea (95%CI) P value
Number of patients 2006 75
2008 94
Investigation with ECO 2006 42 56.0 (44.1, 67.5) 10.0 (−6.0, 25.9) 0.24
2008 62 66.0 (55.5, 75.4)
Investigation with plasma NT-proBNP 2006 32 42.7 (31.3, 54.6) 46.7 (32.7, 60.7) <10−4
2008 84 89.4 (81.3, 94.8)
Treated with ACEI or ARB 2006 45 60.0 (48.0, 71.1) 11.3 (−4.30, 26.9) 0.17
2008 67 71.3 (61.0, 80.1)
ACEI recommended dose 2006 16/45 35.6 (21.9, 51.2) −1.3 (−20.4, 18.0) 1
2008 23/67 34.3 (23.2, 46.9)
Treated with beta-blocker 2006 22 29.3 (19.4, 41.0) 19.6 (4.0, 35.2) 0.015
2008 46 48.9 (38.5, 59.5)
aDiﬀerence between 2008 and 2006.
Table 4: Patients with chronic atrial ﬁbrillation or prior stroke who are treated according to the guidelines.
N Percentage (95%CI) Diﬀerencea (95%CI) P value
Chronic atrial ﬁbrillation
Treated withwarfarin 2006 34/77 44.2 (32.8, 55.9) 6.5 (−10.8, 23.8) 0.52
2008 37/73 50.7 (38.7, 62.6)
Treated with aspirin 320mg if not warfarin 2006 5/43 11.6 (3.9, 25.1) 27.3 (6.1, 48.4) 0.010
2008 14/36 38.9 (23.1, 56.5)
Stroke
Target blood pressure level 2006 31/50b 62.0 (47.2,75.3)
2008 40/59b 67.8 (54.4,79.4)
Treated with recommended anticoagulation 2006 35/48b 72.9 (58.2,84.7)
2008 45/57b 78.9 (66.1,88.6)
aDiﬀerence between 2008 and 2006.
bTwo patients had a bleeding stroke.
Table 5: CHADS2 score of patients with CAF, related to anticoagulation. The table shows the number of patients who are treated with
Warfarin, Aspirin, or no recommended anticoagulation, respectively.
CHADS2 score 2006 N Warfarin Aspirin 320mg No anticoagulation
05 2 0 3
12 0 1 3 0 7
22 2 1 1 2 9
31 2 1 2 9
41 3 4 1 8
55 3 0 2
60 0 0 0
Total number 77 34 5 38
CHADS2 score 2008
05 4 0 1
11 7 1 1 0 6
22 5 9 8 8
31 8 7 6 5
46 5 0 1
52 1 0 1
60 0 0 0
Total number 73 37 14 226 The Scientiﬁc World Journal
between physicians and countries in the management of
HF [17]. HF is objectively diagnosed by ECO, which is
recommended in Swedish guidelines. In our study, 56% of
the patients with HF had been examined with ECO at some
point in 2006. This was increased to 66% (P = 0.24) in 2008
after the intervention. There might be room for even further
improvement, since 75% of Swedish GPs considered ECO
necessary for the diagnosis, according to Remme et al. [17].
We also found a signiﬁcant improvement in the testing of
NT-proBNP, from 43% to 89%, between 2006 and 2008.
Perhaps the test has become more frequently used in general
these years, but the eﬀect of the educational program should
not be underestimated.
Only 43% of European GPs would always, and 51%
often, prescribe an ACEI when treating an HF patient.
Correspondingly, 59% of the Swedish GPs often, and 34%
always, prescribe ACEI. This is similar to the results from
our study where 60% of the HF patients were treated with
ACEIin2006.Theproportionwas71%in2008.Theincrease
is not signiﬁcant (P = 0.17) but is perhaps a positive trend.
Approximately 35% were treated to target dose, both in 2006
and 2008. Larger proportions cannot be expected, since this
patientgroupisdrugsensitiveduetoage.Manypatientshave
renal impairment, which motivate lower target dose.
The use of beta blockade for HF treatment has increased
signiﬁcantly from 29% to 49% (P = 0.015) between our
measure times. According to Remme et al. 65% of Swedish
GPs would add a beta-blocker in a patient who does not
improve despite optimal treatment with a diuretic and an
ACEI. Forty-three percent often prescribe beta blockade
to HF patients [17]. This might indicate an increasing
awareness of the guidelines in Sweden and the improvement
in our study may not only be due to the intervention.
Almost no patient with HF was prescribed NSAID
regularly, which also indicates an awareness of the recom-
mendations.
Chronic atrial ﬁbrillation is common among the elderly
in primary health care, and about half of these patients are
treated with warfarin, according to a Swedish study from
2004 [18]. This is close to our ﬁndings, where 44% were
treated with Warfarin in 2006 and 51% in 2008. According
to the ﬁndings when using CHADS2, the numbers treated
with Warfarin should be higher, since 70% of the patients
had a score of 2 points or more 2008 (68% 2006). With only
one risk factor and CAF, the physician could consider aspirin
as anticoagulation. When this study started, the recommen-
dation was aspirin in the dose 320mg for CAF. We found
a signiﬁcant increase in the use of the recommended dose
between 2006 and 2008 (12% versus 39%, P = 0.01), which
is probably an eﬀect of the intervention. In the guidelines
of 2011, an aspirin dose of 75mg is suggested. There is
no evidence-based data that conﬁrms the optimal dose.
However, in the cases where aspirin could be considered
(score 0-1), no patient out of 22 was treated with aspirin
320mg in 2008. Fourteen out of the ﬁfty-one with higher
scores were treated with aspirin. Perhaps we traditionally
select the wrong patients for anticoagulation.
There is still much to improve regarding compliance to
guidelines. More local education, as in this project, could be
one way. GPs attitudes towards guidelines are yet another
factor to deal with. A Swedish study about attitudes revealed
that the degree of reliance on research data varied among
GPs. Some were convinced of an actual and predictable risk
for the individual; others strongly doubted it. Some were
relying ﬁrmly on protection from disease by pharmaceutical
treatment; others were strongly questioning its eﬀectiveness
in individual cases [19]. A Croatian study among GPs and
internists showed that many primary care physicians use
their own personal experience in prevention while internists
andcardiologistsshowalargertendencytousetheguidelines
[20].
Hence, since we can show an eﬀect of education pro-
grams like the present one, we should encourage a more
widespread use of them. Still we cannot be deﬁnitely sure of
the eﬀect due to the intervention, since some of the positive
results could be explained by an increasing awareness in
the medical community about investigations or some of the
treatments.
More research is needed about optimal treatment, doses,
and targets for these elderly, in order to make the guidelines
more speciﬁc for this population. This would presumably
also increase GPs’ adherence.
This study has some limitations. Firstly we did not have
a control group that was not exposed to the intervention.
This means that we cannot eliminate other inﬂuences on
the results, such as better availability of laboratory and
other tests or wishes of the GPs to conform to local quality
indicators. However, the project is not ﬁrst and foremost an
intervention study, but a description of how it is possible to
work with quality improvement in the clinics and on small
units. Second, we identiﬁed the patients through diagnoses
in the medical records. There might be patients who were
not captured, but there is no reason to believe that they diﬀer
from the investigated patients.
5. Conclusion
By showing that adherence to guidelines about the treatment
of cardiovascular disease is low in primary care, we conﬁrm
the results of previous studies. For example, only approx-
imately one-third of the patients with hypertension reach
target blood pressure. One half of the patients with CAF are
treated with Warfarin, although more than two-thirds have
a CHADS2 score of 2 or more. Educational eﬀorts appear to
increase the adherence and therefore should be encouraged.
Forexample,theuseofbetablockadetoheartfailurepatients
andtheassessmentofNT-proBNPinthesepatientsincreased
signiﬁcantly after the intervention.
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